Dr. Lonn replies [10]

New England Journal of Medicine

Volumn 355, Issue 2, 2006, Pages 209-210

  Lonn, Eva ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; TRACE ELEMENT; VITAMIN B GROUP;

BLOOD PRESSURE MONITORING; CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CYANOCOBALAMIN DEFICIENCY; DIET; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG SAFETY; FOOD INTAKE; HEREDITY; HUMAN; ISCHEMIC HEART DISEASE; LETTER; MACRONUTRIENT; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNITED STATES; UNSTABLE ANGINA PECTORIS; VASCULAR DISEASE; VITAMIN SUPPLEMENTATION;

EID: 33745916458     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-32.
2. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
3. Doll R, Peto R. Mortality in relation to smoking: 20 years' observation on male British doctors. Br Med J 1976;2:1525-36.
4. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.